Abstract: A pharmaceutical dosage form for the release of at least one pharmaceutically active ingredient is claimed. The pharmaceutical dosage form includes a polymer matrix, polymer-lipid nanoparticles incorporated within the matrix and the pharmaceutically active ingredient(s). The polymer matrix is formed from at least two crosslinked cationic and anionic polymers, such as Eudragit® E100 and sodium carboxymethlycellulose. It can also include a neutral polymer, such as one derived from locust bean. The polymer-lipid nanoparticles are formed from at least one polymer, such as Eudragit® E100 and/or chitosan, and at least one phospholipid, such as lecithin. The polymer(s) and phospholipid are crosslinking with a chelating agent, such as sodium tripolyphosphate. The active ingredient or ingredients can be any pharmaceutically active compound(s), and in particular poorly absorbed compounds such as levodopa for the treatment of Parkinson's disease.